Paradigm Biopharmaceuticals Limited (PAR.AX)
Paradigm Biopharmaceuticals Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Melbourne, VIC, AU. The stock last traded at $0.18, up 2.86% on the session, giving a market capitalisation of $107.9M. Its beta of -0.01 implies it has historically moved less than the broad market.
Based in Melbourne, Australia, Paradigm Biopharmaceuticals Limited specializes in the repurposing of existing drugs, developing therapeutic solutions for human health. A central offering is an injectable formulation of pentosan polysulfate sodium, currently undergoing development for the treatment of conditions including osteoarthritis, mucopolysaccharidosis, Ross River virus, chikungunya, and acute respiratory distress syndrome. This company commenced operations in 2014.
Paradigm Biopharmaceuticals Limited is most often compared with the following Healthcare names: